Back
Fulcrum Therapeutics 10K Form
Sell
41
FULC
Fulcrum Therapeutics
Last Price:
3.25
Seasonality Move:
57.36%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive FULC News And Ratings
See the #1 stock for the next 7 days that we like better than FULC
FULC Financial Statistics
Sales & Book Value
Annual Sales: | $2.81M |
---|---|
Cash Flow: | $-19.09M |
Price / Cash Flow: | 0 |
Annual Sales: | $4.77 |
Price / Book: | 0.68 |
Profitability
EPS (TTM): | -0.31000 |
---|---|
Net Income (TTM): | $-17.91M |
Gross Margin: | -- |
Return on Equity: | 0% |
Return on Assets: | 0% |
Fulcrum Therapeutics Earnings Forecast
Key Fulcrum Therapeutics Financial Ratios
- The Research & Development expenses have been 2,559.75% of Revenue.
- The Net Earning history of FULC is -3,470.05% of Total Revenues.
- Per Share Earnings over the last 7 years have been positive in 4 years.
Fulcrum Therapeutics Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Pharmaceuticals |
Sector: | Health Care |
Current Symbol: | FULC |
CUSIP: | 359616 |
Website: | fulcrumtx.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 0 |
Quick Ratio: | 0 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
FULC Technical Analysis vs Fundamental Analysis
Sell
41
Fulcrum Therapeutics (FULC)
is a Sell
Is Fulcrum Therapeutics a Buy or a Sell?
-
Fulcrum Therapeutics stock is rated a Sell
The current Fulcrum Therapeutics [FULC] share price is $3.25. The Score for FULC is 41, which is 18% below its historic median score of 50, and infers higher risk than normal.